(Q38787053)

English

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

scientific article published on 11 May 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

10

object named as

Tore K Kvien

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Jørgen Jahnsen

9

object named as

Jørgen Jahnsen

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Kristin K Jørgensen

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Inge C Olsen

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Guro L Goll

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Merete Lorentzen

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Nils Bolstad

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Espen A Haavardsholm

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Knut E A Lundin

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Cato Mørk

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

NOR-SWITCH study group

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

11 May 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

389

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

10086

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

2304-2316

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inequities in access to biologic and synthetic DMARDs across 46 European countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilars in rheumatology: the wind of change

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The changing landscape of biosimilars in rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilars: the science of extrapolation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The challenge of indication extrapolation for infliximab biosimilars

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biosimilars in rheumatology: current perspectives and lessons learnt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring Crohn's disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930068-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)30068-5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38787053&oldid=1786867634"